Literature DB >> 9153643

The apolipoprotein E epsilon4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease.

L Minthon1, C Hesse, M Sjögren, E Englund, L Gustafson, K Blennow.   

Abstract

The apolipoprotein (apoE) epsilon4 allele was studied in fronto-temporal dementia (FTD), a diagnostic category including the specific disorders Pick's disease and frontal lobe degeneration of non-Alzheimer type (FLD). These dementing diseases have neuronal and synaptic degeneration in common with Alzheimer's disease (AD), for which the presence of the apoE epsilon4 allele is a known risk factor, and lowers the age of onset of disease. Previous studies on the apoE epsilon4 allele frequency in FTD have been inconclusive. The structural hallmarks of AD, allegedly linked to apoE presentation, neuritic plaques (NP), primarily composed of aggregates of beta-amyloid, and neurofibrillary tangles (NFT), primarily composed of hyperphosphorylated tau, are lacking in FTD. However, tau-positive cytoskeletal pathology is found in Pick's disease, but not in FLD. Resolving whether the epsilon4 frequency is increased in FTD or not may thus give clues to the pathogenetic mechanism of apoE in AD. We therefore studied apoE alleles in a well characterized material of FTD patients. The epsilon4 allele frequency was similar in 25 patients with FTD (14.0%) as compared with 26 healthy controls (13.5%). A post-mortem neuropathological examination was performed in 10 cases (nine had FLD and one Pick's disease). Our finding of a normal epsilon4 allele frequency in our group of FTD, principally consisting of FLD cases, support hypotheses involving differential binding of apoE to beta-amyloid and/or tau, in the development of beta-amyloid deposition and NP formation and/or tau hyperphosphorylation and NFT formation, for the pathogenetic role of apoE in AD. The age at onset was significantly lower (P < 0.01) in FTD patients possessing the epsilon4 allele (48.7 +/- 8.0 years) than in patients not possessing this allele (58.9 +/- 7.6 years). We conclude that, although the apoE epsilon4 allele frequency is not increase in FTD, the epsilon4 allele is not an etiological factor, but may rather be an accelerating factor in the degenerative process of FTD, thereby resulting in an earlier presentation of the disorder in individuals predisposed to develop FTD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9153643     DOI: 10.1016/s0304-3940(97)00230-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  Apolipoprotein Ε ε4 frequency is increased among Chinese patients with frontotemporal dementia and Alzheimer's disease.

Authors:  Yong Ji; Mengyuan Liu; Ya Ruth Huo; Shuling Liu; Zhihong Shi; Shuai Liu; Thomas Wisniewski; Jinhuan Wang
Journal:  Dement Geriatr Cogn Disord       Date:  2013-07-23       Impact factor: 2.959

2.  Folate/Vitamin B Alleviates Hyperhomocysteinemia-Induced Alzheimer-Like Pathologies in Rat Retina.

Authors:  Jing Guo; Shaozhou Ni; Qihang Li; Jian-Zhi Wang; Ying Yang
Journal:  Neurosci Bull       Date:  2018-09-28       Impact factor: 5.203

3.  Identification of misdiagnosed fronto-temporal dementia using APOE genotype and phenotype-genotype correlation analyses.

Authors:  Isabel Hernández; Ana Mauleón; Maiteé Rosense-Roca; Montserrat Alegret; Georgina Vinyes; Anna Espinosa; Oscar Sotolongo-Grau; James T Becker; Sergi Valero; Lluís Tarraga; Oscar L López; Agustín Ruiz; Mercè Boada
Journal:  Curr Alzheimer Res       Date:  2014-02       Impact factor: 3.498

4.  The apolipoprotein E epsilon4 allele selectively increases the risk of frontotemporal lobar degeneration in males.

Authors:  R Srinivasan; Y Davidson; L Gibbons; A Payton; A M T Richardson; A Varma; C Julien; C Stopford; J Thompson; M A Horan; N Pendleton; S M Pickering-Brown; D Neary; J S Snowden; D M A Mann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

5.  Novel progranulin mutations with reduced serum-progranulin levels in frontotemporal lobar degeneration.

Authors:  Huei-Hsin Chiang; Charlotte Forsell; Lena Lilius; Linn Öijerstedt; Steinunn Thordardottir; Krishnan Shanmugarajan; Marie Westerlund; Inger Nennesmo; Håkan Thonberg; Caroline Graff
Journal:  Eur J Hum Genet       Date:  2013-03-06       Impact factor: 4.246

6.  Updated meta-analysis of the role of APOE ε2/ε3/ε4 alleles in frontotemporal lobar degeneration.

Authors:  Wen-Hua Su; Zhi-Hong Shi; Shu-Ling Liu; Xiao-Dan Wang; Shuai Liu; Yong Ji
Journal:  Oncotarget       Date:  2017-07-04

7.  Plasma cholesterol in Alzheimer's disease and frontotemporal dementia.

Authors:  Pan Wang; Huihong Zhang; Yan Wang; Miao Zhang; Yuying Zhou
Journal:  Transl Neurosci       Date:  2020-05-18       Impact factor: 1.757

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.